

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark Player et al.)
Application No. 10/673,521) Art Unit: 1614
Filed: September 30, 2003) Examiner: Not Assigned
For: 4,6-Diaminosubstituted-2-[Oxy or Aminoxy] [1,3,5]Triazines as Protein Tyrosine Kinase Inhibitors	-)))

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. § 1.56 and § 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 forms. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

With the except of U.S. Patent Applications and U.S. Patents, copies of the documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: March 3, 2004 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania, N.W. Washington, D.C. 20004

Tele: 202-739-3000 Fax: 202-739-3001

Respectfully submitted,
Morgan, Lewis & Bockius LLP

Gregory T. Lowen

Registration No. 46,882 Direct Dial: 202-739-5915



INFORMATION DISCLOSURE CITATION

Attorney Docket **038073-5002**

Application No. 10/673,521

(Use several sheets if necessary)

Applicant: Mark Player et al.

Page 1 of 2

PTO Form 1449

Filing Date: September 30, 2003

Group Art Unit: 1614

U.S. PATENT DOCUMENTS

U.S. FATENT DOCUMENTS								
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date	
	aa	2002/0065270	05/30/2002	Moriarty et al.	514	218	12/22/2000	
	ab	3,563,971	02/16/1971	Wood et al.	260	93.7	09/26/1968	
	ac	4,816,064	03/28/1989	Konno et al.	504	234	11/20/1986	
	ad	5,153,245	10/06/1992	Cipolli et al.	524	100	09/09/1991	
	ae	5,304,646	04/19/1994	Cipolli et al.	544	204	04/22/1993	
	af	5,429,949	07/04/1995	Radosevich et al.	435	252.1	02/22/1994	
	ag	5,508,193	04/16/1996	Mandelbaum <i>et al</i> .	435	253.3	08/31/1993	
	ah	5,629,382	05/13/1997	Cipolli et al.	525	158	09/16/1994	
	aj	5,811,081	09/22/1998	Fuso et al.	424	59	09/27/1995	
	ak	6,100,254	08/08/2000	Budde et al.	514	221	10/10/1997	
	al	6,235,746	05/22/2001	Davis et al.	514	275	02/16/1999	
	am	6,284,522	09/04/2001	Wackett et al.	435	262.5	10/23/1995	
	an	6,342,395	01/29/2002	Hammock et al.	436	518	04/22/1998	
	ao	6,346,625	02/12/2002	Karabelas et al.	548	312.1	01/20/2000	
	ap	6,383,790	05/07/2002	Shokat	435	194	01/11/2000	
	aq	6,395,562	05/28/2002	Hammock et al.	436	518	09/04/1998	

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
ar	WO 93/12094	06/24/1993	PCT			
as	WO 95/05366	/ 02/23/1995	PCT			
at	WO 96/06836	03/07/1996	PCT			
au	WO 97/03642	02/06/1997	PCT			
av	WO 97/03643	02/06/1997	PCT			
aw	WO 97/35580 /	10/02/1997	PCT			
ax	WO 97/37660 /	10/16/1997	PCT			
ay	WO 99/01442	01/14/1999	PCT			
az	WO 00/18759	04/06/2000	PCT			<u> </u>
ba	WO 00/32575	06/08/2000	PCT			
bb	WO 00/41526	07/20/2000	PCT			
bc	WO 00/43369 /	07/27/2000	PCT			
bd	WO 00/48004 /	08/17/2000	PCT			
be	WO 00/67900 <	11/16/2000	PCT			
bf	WO/00/73276 <	12/07/2000	PCT			
bg	WO 00/78757 <	12/28/2000	PCT			

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

Attorney Docket **038073-5002**

Application No.

5002 10/673,521

(Use several sheets if necessary)

Applicant: Mark Player et al.

Page 2 of 2

PTO Form 1449

Filing Date: September 30, 2003

Group Art Unit: 1614

FOR	EIGN	PATENT	DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
bh	WO 01/47897	07/05/2001	PCT	0.000		
bi	WO 01/47921	07/05/2001	PCT			
bj	WO 01/58899	08/16/2001	PCT			
bk	WO 01/94346	12/13/2001	PCT			
bl	0 365 818 A1	05/02/1990	Europe			
bm	0 475 364 A1	03/18/1992	Europe			
bn	0 475 368 A2	03/18/1992	Europe			
bo	0 627 428 A1	12/07/1994	Europe			
bp	0 634 412 A1	01/18/1995	Europe			
bq	GB 2 311 788 A	10/08/1997	Great Britain	<u> </u>		
br	3-241069	10/28/1991	Japan			
bs	3-241089	10/28/1991	Japan			

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.